GlassScriptPhysician profile
Brian R Collins
NPI 1063647576
$8,229.81
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,388 · 2020: $1,857 · 2021: $2,240 · 2022: $1,462 · 2023: $257 · 2024: $25.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $282.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,516.49 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,259.15 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $960.94 | 2019-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $780.23 | 2019-2023 | Eliquis |
| Amgen INC. | $522.89 | 2019-2022 | |
| Abbott Laboratories | $500.16 | 2019-2022 | |
| Biotronik INC. | $449.76 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $336.76 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $296.64 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.99 | 2019-2022 | |
| Gilead Sciences, INC. | $178.50 | 2019-2024 | |
| Pfizer INC. | $178.32 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $170.90 | 2019 | |
| Cvrx, INC. | $168.57 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $164.53 | 2021-2023 | Pifeltro, Delstrigo, Dificid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $101.83 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $87.53 | 2021 | |
| Esperion Therapeutics, INC. | $68.43 | 2020-2021 | |
| Boston Scientific Corporation | $60.05 | 2021 | |
| Alnylam Pharmaceuticals INC. | $52.22 | 2019-2022 | |
| Medtronic, INC. | $49.24 | 2021-2023 | Cobalt Dr Mri Surescan |
| Daiichi Sankyo INC. | $25.01 | 2022 | |
| Medtronic Vascular, INC. | $24.91 | 2020 | |
| Novo Nordisk INC | $23.30 | 2022 | |
| Amarin Pharma, INC. | $22.07 | 2021 | |
| Lilly USA, LLC | $17.98 | 2022 | |
| Viiv Healthcare Company | $17.57 | 2023 | Apretude |
| Arbor Pharmaceuticals, INC. | $15.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.